Failure For AZ’s Imfinzi In CALLA Strengthens Keytruda’s Cervical Cancer Hold
Early Setting Left Underserved
An unexpected miss for AstraZeneca’s checkpoint inhibitor Imfinzi in cervical cancer, in the wake of other rivals dropping out, leaves Merck & Co’s Keytruda more firmly in command of the market.
You may also be interested in...
Merck said the KEYNOTE-A18 trial in newly diagnosed, high-risk locally advanced patients met its PFS co-primary endpoint, while results for the OS endpoint were not yet mature.
Pivotal data presented at the ASCO GI meeting in liver and biliary tract cancers could add a couple of billion dollars to Imfinzi’s sales and breathe new life into the CTL4 inhibitor tremelimumab.
The company announced it would withdraw the BLA for balstilimab monotherapy in cervical cancer following Keytruda’s full approval, but it plans to keep developing the drug.